论文部分内容阅读
目的:探讨仙台病毒Tianjin株(SeV)及其核酸制备预防人副流感病毒I型(hPIV-1)疫苗的可行性。方法(:1)用SeV免疫小鼠3次后取血清,间接ELISA法检测免疫血清抗体效价。(2)将倍比稀释的免疫血清与100 TCID50/0.1 ml的hPIV-1进行中和实验,观察细胞病变(CPE)并计算50%血清中和终点。(3)构建SeV真核表达质粒pVAX1-F、pVAX1-HN,分别单独或联合免疫小鼠,取免疫血清检测对hPIV-1的中和终点。结果:SeV免疫血清抗体的50%中和终点分别为39.8、12.6、16.0、44.7、25.1;质粒免疫血清抗体的中和作用按pVAX1-HN+pVAX1-F组>pVAX1-HN组>pVAX1-F组依次递减。结论:仙台病毒Tianjin株及其HN基因、F基因真核表达质粒能诱导机体产生抗hPIV-1抗体,有可能成为制备预防hPIV-1疫苗的有效毒株。
Objective: To investigate the feasibility of preparing Sendai virus Tianjin strain (SeV) and its nucleic acid preparation for preventing human parainfluenza virus type I (hPIV-1) vaccine. Methods: (1) SeV immunized mice with SeV three times after the sera were taken, indirect ELISA was used to detect the antibody titer of immune sera. (2) Neutralize the multiplied diluted immune serum with 100 TCID50 / 0.1 ml of hPIV-1, observe cytopathic effect (CPE) and calculate 50% serum neutralization end point. (3) SeV eukaryotic expression plasmids pVAX1-F and pVAX1-HN were constructed, and the mice were immunized separately or in combination. The neutralization end point of hPIV-1 was detected by immune sera. Results: The 50% neutralization endpoints of SeV immune serum antibodies were 39.8, 12.6, 16.0, 44.7 and 25.1, respectively. Neutralization of antibody against serum plasmids was as follows: pVAX1-HN + pVAX1-F group> pVAX1- Group in descending order. Conclusion: The Tianjin strain of Sendai virus and its HN gene and F gene eukaryotic expression plasmid can induce the body to produce anti-hPIV-1 antibody, which may become an effective strain for preparing vaccine against hPIV-1.